- Meeting abstract
- Open Access
Microelements as risk factors for cancer of the lung and larynx
- Katrzyna Jaworska-Bieniek1, 2,
- Satish Gupta1, 2,
- Katarzyna Durda1,
- Magdalena Muszynska1,
- Grzegorz Sukiennicki1,
- Elżbieta Jaworowska3,
- Tomasz Grodzki4,
- Mieczysław Sulikowski5,
- Piotr Woloszczyk6,
- Janusz Wójcik4,
- Jakub Lubiński3,
- Cezary Cybulski1,
- Tadeusz Dębniak1,
- Marcin Lener1,
- Steven A Narod7,
- Ping Sun7,
- Jan Lubiński1 and
- Anna Jakubowska1
© Jaworska-Bieniek et al; licensee BioMed Central Ltd. 2012
Published: 10 December 2012
Selenium deficiency has been suggested by several studies to be associated with cancer risk. We conducted a case-control study in Szczecin, a region of northwestern Poland, on 86 cases of lung cancer, 87 cases of laryngeal cancer and an equal number of healthy controls. We studied the serum level of selenium and genotypes for four variants in four selenoprotein genes (GPX1, GPX4, TXNRD2 and SEP15) and the odds of being diagnosed with lung or laryngeal cancer.
Among lung cancer cases, the mean selenium level was 63.2 µg/l, compared to a mean level of 74.7 µg/l for their matched controls (p < 0.0001). Among laryngeal cancer cases, the mean selenium level was 64.8 µg/l, compared to a mean level of 76.3 µg/l for their matched controls (p < 0.0001). Compared to a serum selenium value in the lowest of four categories (≤ 60 µg/l) a selenium level in the highest category (> 80 µg/l) was associated with an odds ratio of 0.10 (95% CI 0.03 to 0.34; p = 0.0002) for lung cancer and 0.24 (95% CI 0.10 to 0.59; p = 0.002) for laryngeal cancer. In four selenoproteins studied here we found a modest associations of genetic variants in GPX1 and GPX4 with lung and TXNRD2 with laryngeal cancer risk.
We analyzed iron (Fe) level in serum of 77 lung cancer patients and 77 matched controls. We did not find difference in mean Fe level between cases and controls (1053.05 µg/l and 1059.39 µg/l). However, we found that Fe level in the lowest and highest quartiles was associated with a significant lung risk enhancement when compared to a serum Fe level in the middle quartiles (OR 0.3, p 0.02). We also observed that the relationship between the level of Fe and Se could be an important factor for lung cancer risk.
Se is the strong marker of high risk of lung and laryngeal cancers and can be potentially used for detection of early cancers. Based on data showing higher Se supplementation as to be associated with lower cancer mortality (OR.55) Se supplementation should be considered to all patients with already diagnosed cancer.
Very low and very high Fe level seems to be associated with increased lung cancer risk
Most probably, for exact cancer risk assessment it will be necessary to analyze relationships between microelements, ie. Fe/Se ratio.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.